Clinically, JAK inhibitors (e.g., tofacitinib) already approved for autoimmune diseases show promise in preclinical models by reducing IL-6/STAT3-driven EMT (38), while TLR4 or NLRP3 inhibitors could blunt the initial DAMP-induced inflammatory cascade that seeds EMT (29). Here, STAT3 is linked to autoimmune disease.